Dec 21, 2005
FLAMEL ANNOUNCES GLAXOSMITHKLINE SUBMISSION OF NDA FOR MICROPUMP-ENABLED, CURRENTLY MARKETED GSK DRUG
Oct 28, 2005
Flamel Technologies Announces Third Quarter Results, Earnings of $0.13 Per Share and Revenues of $13.3 Million
Oct 26, 2005
Flamel Technologies Announces Successful Phase III Results in Connection with its Collaboration with GlaxoSmithKline
Oct 26, 2005
Flamel Technologies Announces Third Quarter Results
Oct 24, 2005
Flamel Technologies Announces Election of New Members of the Board of Directors; Results of Extraordinary General Meeting
Oct 21, 2005
Flamel Technologies Announces Projected Release Date of Third Quarter Results, Conference Call
Oct 06, 2005
Flamel Technologies Appoints Michel Finance as Chief Financial Officer
Sep 23, 2005
Flamel Technologies Announces Positive Preliminary Results of a Phase I/II Trial of IFN-alpha-XL in Patients with Chronic Hepatitis C Virus Infection
Sep 22, 2005
Flamel Technologies Announces New Nominees for Board of Directors, Extraordinary General Meeting
Sep 19, 2005
UBS Global Life Sciences Conference to Webcast Flamel Technologies Corporate Presentation
Sep 05, 2005
Flamel Technologies announces notification of termination of the license of Flamel's Micropump® Technology to TAP Pharmaceutical Products Inc. for Lansoprazole
Jul 27, 2005
Flamel Technologies Announces Second Quarter Results
Jul 21, 2005
Flamel Technologies Announces Projected Release Date
of Second Quarter Results, Conference Call
Jun 22, 2005
Flamel Technologies Announces Election of New Board at Annual Meeting of Shareholders
Jun 14, 2005
Flamel announces patent filing for Trigger Lock™ System to Prevent Opioid Misuse and Abuse
Jun 13, 2005
Flamel Technologies Announces Filing of Announces patent filing for ''combination of Asacard with COX-2 inhibitors''
May 05, 2005
Flamel Technologies Announces First Quarter Results,
Including Milestone from TAP Pharmaceuticals
Apr 29, 2005
Flamel Technologies Announces Announces Projected Release Date of First Quarter Results, Conference Call
Mar 11, 2005
Flamel Technologies Announces Fourth Quarter and Year-End Results; Fourth Quarter Results Show Profit of $0.28 per Diluted Share on License and Research Revenue Growth
Mar 07, 2005
Flamel Technologies Announces Results of Meeting of Shareholders;
Sets Projected Release Date for 2004 Results and Conference Call
Mar 03, 2005
Flamel Technologies Announces Announces Termination of Licensing Agreement for Genvir® and Recovery of Rights
Feb 07, 2005
Flamel Technologies Announces Public Release of Phase IIa data on Basulin®
Jan 31, 2005
Flamel Technologies Announces Payment from Bristol-Myers Squibb to Flamel as well as Recovery of Rights to Data, including Phase IIa Results
Jan 26, 2005
Flamel Technologies Announces New Composition of its Scientific Advisory Board
